Atrium Therapeutics Launches with $270M to Fund RNA Therapies for Rare Cardiomyopathies
Atrium Therapeutics launched as an independent Nasdaq-listed company with $270 million in cash to advance two RNA-based therapies targeting PRKAG2 syndrome and PLN cardiomyopathy. Lead candidates ATR 1072 and ATR 1086 are poised for IND filings in 2H26 and 2027, respectively, with two additional research targets in development.
1. Launch and Funding
Atrium Therapeutics began independent operations following its separation from Novartis’s Avidity Biosciences acquisition, listing on Nasdaq and securing approximately $270 million in cash and cash equivalents. The company is led by CEO Kathleen Gallagher and board chair Sarah Boyce, positioning it to fund early-stage precision cardiology programs.
2. Pipeline and Development Timeline
Atrium’s lead candidate, ATR 1072 for PRKAG2 syndrome, is advancing IND-enabling studies with a planned filing in the second half of 2026. ATR 1086 for PLN cardiomyopathy is set to commence CMC manufacturing this year, targeting IND submission in 2027, and both programs could enter clinical trials pending supportive Phase 1 data.
3. Technology and Future Targets
Building on a targeted RNA delivery platform combining monoclonal antibody selectivity with oligonucleotide precision, Atrium aims to address genetically driven cardiomyopathies at their molecular roots. In addition to its two lead assets, the company holds two undisclosed research targets and plans to develop next-generation delivery methods for heart-specific siRNA therapies.